Research programme: CAR imaging agents - Vascular BioSciences
Latest Information Update: 17 Sep 2024
Price :
$50 *
At a glance
- Originator Vascular BioSciences
- Class Cyclic peptides; Imaging agents
- Mechanism of Action Image enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections; Pulmonary hypertension; Sepsis
Most Recent Events
- 11 Sep 2024 Preclinical trials in COVID-2019 infections (Diagnosis) in USA (Parenteral) prior to September 2024 (Vascular BioSciences pipeline, September 2024)
- 11 Sep 2024 Preclinical trials in Pulmonary hypertension (Diagnosis) in USA (Parenteral) prior to September 2024 (Vascular BioSciences pipeline, September 2024)
- 11 Sep 2024 Preclinical trials in Sepsis (Diagnosis) in USA (Parenteral) prior to September 2024 (Vascular BioSciences pipeline, September 2024)